A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects With Neurofibromatosis Type 1 in Children and Adults

Study Overview

The purpose of this Phase II Study is to determine the response rate of NFI patients with plexiform neurofibromas treated with Cabozantinib therapy using MRI scans.

Study Description

This phase II open label study will evaluate adolescents and adults with neurofibromatosis type-1 (NF1) and plexiform neurofibromas treated with cabozantinib (XL184).

Additional Information

Participants will not be paid for their participation.


  • IRB Number: 1305011412 (1305005374) (CABOZANTINIB)
  • Research Study Identifier: TX3396
  • Principal Investigator: Michael Ferguson, MD

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176